These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30603323)

  • 1. Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks.
    Iwahashi Y; Hirose S; Nakajima S; Seo A; Takahashi T; Tamori Y
    Diabetol Int; 2017 Jun; 8(2):205-211. PubMed ID: 30603323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirose S; Nakajima S; Iwahashi Y; Seo A; Takahashi T; Tamori Y
    Intern Med; 2016; 55(22):3239-3245. PubMed ID: 27853064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.
    Suzuki M; Takeda M; Kito A; Fukazawa M; Yata T; Yamamoto M; Nagata T; Fukuzawa T; Yamane M; Honda K; Suzuki Y; Kawabe Y
    Nutr Diabetes; 2014 Jul; 4(7):e125. PubMed ID: 25000147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes.
    Kakuda H; Kobayashi J; Sakurai M; Takekoshi N
    J Clin Med Res; 2019 Jan; 11(1):35-41. PubMed ID: 30627276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
    Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
    J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.
    Kakuda H; Kobayashi J; Sakurai M; Kakuda M; Takekoshi N
    J Clin Med Res; 2017 May; 9(5):403-409. PubMed ID: 28392860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
    Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes.
    Sato M; Tamura Y; Kaga H; Yamasaki N; Kiya M; Kadowaki S; Sugimoto D; Funayama T; Someya Y; Kakehi S; Nojiri S; Satoh H; Kawamori R; Watada H
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
    Ishibashi Y; Matsui T; Yamagishi SI
    Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Diabetes Ther; 2021 Sep; 12(9):2499-2515. PubMed ID: 34357559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.
    Obara K; Shirakami Y; Maruta A; Ideta T; Miyazaki T; Kochi T; Sakai H; Tanaka T; Seishima M; Shimizu M
    Oncotarget; 2017 Aug; 8(35):58353-58363. PubMed ID: 28938561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
    Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
    Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
    Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T
    Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.